Scancell (LON:SCLP) Reaches New 1-Year Low – Here’s Why

Scancell Holdings plc (LON:SCLP)’s stock price reached a new 52-week low during trading on Thursday. The stock traded as low as GBX 88 and last traded at GBX 88, with a volume of 538,124 shares changing hands. The stock had previously closed at GBX 89.

Scancell Price Performance

The firm has a 50-day simple moving average of GBX 95.45 and a two-hundred day simple moving average of GBX 133.20. The company has a market capitalization of £1.20 billion, a price-to-earnings ratio of -160.36 and a beta of 0.69. The company has a current ratio of 0.28, a quick ratio of 13.01 and a debt-to-equity ratio of -88.01.

Scancell (LON:SCLP) last released its quarterly earnings data on Friday, October 9th. The company reported GBX (17.30) earnings per share for the quarter. Scancell had a negative net margin of 116.98% and a positive return on equity of 128.87%. As a group, analysts predict that Scancell Holdings plc will post -2.54 earnings per share for the current fiscal year.

About Scancell

Scancell (LSE:SCLP) is a clinical stage company leveraging two proprietary platforms, Immunobody® and Moditope®, to develop targeted off-the-shelf, patient-accessible active immunotherapies for a cancer-free future. The lead product iSCIB1+ is an Immunobody® DNA active immunotherapy that has demonstrated monotherapy activity in adjuvant melanoma. When combined with checkpoint therapies it showed additional clinical benefit over the checkpoints (CPI) alone in the ongoing Phase 2 SCOPE trial in advanced melanoma.